# Pharmaceuticals Bayer

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/pharmaceuticals-bayer/

## Facts

| Field | Value |
| --- | --- |
| Country | DE |
| OpenAlex ID | https://openalex.org/F4320335359 |
| Works | 333 |

## Funder papers

- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF](https://scholariq.org/papers/effect-of-finerenone-on-the-kccq-in-patients-with-hfmref-hfpef/)
- [Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction](https://scholariq.org/papers/efficacy-and-safety-of-finerenone-in-heart-failure-with-preserved-ejection/)
- [Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)](https://scholariq.org/papers/impact-of-baseline-glp-1-receptor-agonist-use-on-albuminuria-reduction-and/)
- [Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia](https://scholariq.org/papers/impact-of-simultaneous-initiation-of-finerenone-and-empagliflozin-on-urinary/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.